TY - JOUR
T1 - Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP
T2 - A single-center experience.
AU - Devi, Kanta
AU - Shaikh, Muhammad Usman
AU - Ali, Natasha Bahadur
AU - Adil, Salman Naseem
AU - Khan, Maria
AU - Soomar, Salman Muhammad
N1 - Funding Information:
We would like to acknowledge and thank Department of Oncology, Aga Khan University Hospital for their logistic support and Department of Health Management and Information Systems (HIMS), Aga Khan University Hospital for their support in data processing.
Publisher Copyright:
© 2021
PY - 2021/1
Y1 - 2021/1
N2 - In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.
AB - In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.
KW - Diffuse large B-cell lymphoma
KW - Non-hodgkin lymphoma
KW - R-CHOP
KW - R-DA-EPOCH
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85120432634&partnerID=8YFLogxK
U2 - 10.1016/j.lrr.2021.100284
DO - 10.1016/j.lrr.2021.100284
M3 - Article
AN - SCOPUS:85120432634
SN - 2213-0489
VL - 16
JO - Leukemia Research Reports
JF - Leukemia Research Reports
M1 - 100284
ER -